This text, the proceedings of the 32nd International Conference on Transplantation and Clinical Immunology, held in Lyon, France, on May 25-26, 2000, addresses novel issues in terms of changing indications for transplantation in the management of organ failure, whether humans will remain the only source for organ procurement, prospects for engineering in organ replacement, and whether transplantation will remain the most appropriate approach to organ failure. Some promising treatments are approached, such as enzymic and biochemical replacement, gene therapy, tolerance induction, stem cell transplantation, and xenotransplantation. In addition to the constant improvement in conservative management of organ failure in general, ongoing research in selected fields is reported in the proceedings, such as: liver transplantation vs artificial liver; novel dialysis strategies vs evolving immunosuppression in kidney transplantation; islets transplantation and external implantable insulin pumps vs pancreas transplantation in diabetic patients and circulatory assistance and intramyocardial myoblast injection vs heart transplantation. Pivotal experience in selected emerging transplantations is included, that is, small bowel, limb, skin and neuronal transplantation. Such fascinating perspectives raise medical, economical, and ethical problems which are discussed in this book.

Immunosuppression in solid organ transplantation is experiencing a worldwide revival since new drugs are now available in the late-1990s and others are under development. In order to contribute to the design of future strategies, a critical approach of surrogate endpoints is given and long-term side effects are analyzed, together with the impact of non-compliance, quality-of-life and economical parameters. In this book, international specialists have set up the scientific rationale and provided new bases for further immunosuppressive strategies.

Immunosuppression in solid organ transplantation is currently experiencing a worldwide revival since new drugs are now available and others are under development. In order to contribute to the design of future strategies, a critical approach of surrogate endpoints is given and long-term side effects are analysed, together with the impact of non-compliance, quality-of-life and economical parameters. In this book, international specialists have set up the scientific rationale and provided new bases for further immunosuppressive strategies.

This book, the proceedings of the 32nd International Conference on Transplantation and Clinical Immunology, held in Lyon, France, on May 25-26, 2000, addresses novel issues in terms of changing indications for transplantation in the management of organ failure, whether humans will remain the only source for organ procurement, prospects for engineering in organ replacement, and whether transplantation will remain the most appropriate approach to organ failure. Some promising treatments are approached, such as enzymic and biochemical replacement, gene therapy, tolerance induction, stem cell transplantation, and xenotransplantation. In addition to the constant improvement in conservative management of organ failure in general, ongoing research in selected fields is reported in the proceedings, such as liver transplantation vs artificial liver, novel dialysis strategies vs evolving immunosuppression in kidney transplantation, islets transplantation and external implantable insulin pumps vs pancreas transplantation in diabetic patients, circulatory assistance and intramyocardial myoblast injection vs heart transplantation. Pivotal experience in selected emerging transplantations is included, that is, small bowel, limb, skin and neuronal transplantation. Such fascinating perspectives raise medical, economical, and ethical problems which are discussed in this book.

When a grafted part fails to take, it is usually because of acute or chronic rejection, either for strictly immunological reasons or because of failure to properly follow the immunosuppressive therapy. There are other reasons for loss of a transplant however, notably when the disease that led to a kidney transplant returns after the operation, something that happens in 5 to 15% of cases. This book aims to: Review the current state of knowledge and methods of care; Suggest therapeutic consensus, especially in cases of nephrotic syndrome, by using specific post-transplant treatment or preventive measures; Connect up the various practices concerning choice of donors; Spell out more clearly the approach to take when a first transplant fails and another is envisaged; Sponsored by the Merieux Foundation and the work of leading international experts in the field, the book provides indispensable top-quality information.